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arrest by degradation of p27 through a MEK/Erk/SKP2-dependent pathway
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Objective. To examine whether oncogenic Ras affects transforming growth factor (TGF)-b–
mediated cell-cycle arrest in hematopoietic cells and the downstream signal transduction
pathway involved in the interference with TGF-b–induced cell-cycle arrest.
Materials and Methods. Two leukemic cell lines bearing N-RasL61 mutations; HL-60 and TF-
1, and the M1 cell line with wt Ras were investigated for their response to TGF-b. Signal
transduction inhibitors, overexpression and RNA interference studies were performed to
investigate the involvement of the various proteins.
Results. Although TGF-b signal transduction was not affected, G0-G1 arrest was absent in
HL-60 and TF-1 cells due to the absence of p27. Overexpression of p27 restored TGF-b–
induced cell-cycle arrest, as well as interfering in Ras-mediated signaling. The farnesyl
transferase inhibitor L744832 and the MEK inhibitor U0126 both restored p27 levels and
cell-cycle arrest in response to TGF-b. The absence of p27 protein is due to elevated levels
of the ubiquitin ligase SKP2, which complexes with and targets p27 for degradation. RNA
interference for SKP2 and treatment of these cells with the proteasome inhibitor MG132
restored p27 levels, corresponding with decreasing SKP2 levels after interfering in N-Ras
signal transduction. P27, phosphorylated at threonine 187, is nuclear localized in N-Ras–
containing cells. Mutation of this residue to alanine rendered p27 insensitive to
degradation.
Conclusion. N-RasL61 transformed cells lack a G0-G1 arrest upon TGF-b treatment due to
absence of p27. p27 is degraded through a MapK-, and SKP2-dependent pathway. Over-
expression of p27 results in restoration of cell-cycle arrest upon TGF-b treatment.  2005
International Society for Experimental Hematology. Published by Elsevier Inc.Transforming growth factor-β (TGF-β) and Ras-signal trans-
duction have opposite effects on cell proliferation. Where
Ras and downstream mitogen-activated protein kinase/extra-
cellular signal regulated kinase kinase (MEK/Erk) signaling
are induced in response to growth promoting factors [1,2],
cell growth is arrested in response to TGF-β [3–5]. Binding
of TGF-β to its receptor leads to activation of Smad proteins
and modulates the transcription of many target genes, includ-
ing genes that affect cell fate [3,4].
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doi: 10.1016/ j .exphem.2005.04.006TGF-β–induced cell-cycle arrest is mediated by various
cyclin-dependent kinase inhibitors (CDKi), including
p15Ink4B [6,7], p21Waf1/Cip1 [8,9], p27Kip1 [10,11], and p57Kip2
[12]. Furthermore, expression and activity of additional pro-
teins, such as c-Myc, cyclin A, CDK4/6, and the phosphatase
cdc25A, are suppressed by TGF-β [13,14]. These events
eventually lead to decreased activity of the Cyclin D-CDK4/
6 and Cyclin E-CDK2 complexes and ultimately result in
cell-cycle arrest.
One of the key intermediates in TGF-β–induced cell-
cycle arrest is the CDKi p27Kip1 and alterations in protein
levels or localization interfere with the inhibitory activity
on CDK2 and TGF-β–induced cell-cycle arrest [13,15–17].
Regulation of p27 is primarily controlled by phosphorylation
and subsequent degradation or proteolysis by two distinctExperimental Hematology. Published by Elsevier Inc.
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by the CDK2-Cyclin E complex targets p27 for ubiquiti-
nation in the nucleus by the E3 ubiquitin ligase SKP2
[18–24]. This ubiquitinated p27 is then degraded by the
26S proteasome [22,23,25]. Phosphorylation of p27 on other
residues, such as Serine 10, Threonine 157, and Threonine
198, leads to cytoplasmic translocation, where p27 is either
degraded or stabilized [26–32]. Cytoplasmic p27 has no
inhibitory effect on the cell cycle.
Besides inactivating mutations in the TGF-β receptors or
Smad proteins [3], TGF-β–mediated cell-cycle arrest can be
blocked by oncogenic Ras. This has been attributed to MAP
kinase-dependent phosphorylation of Smad 2/3 and subse-
quent impaired nuclear translocation, degradation of Smad
4, or mislocalization of p27 to the cytoplasm [13,33,34].
In acute myeloid leukemia (AML), cytoplasmic mislocal-
ization of p27 is associated with constitutive Akt phosphory-
lation and unfavorable prognosis [35]. In addition, Akt
phosphorylation might depend upon Ras activation [36].
Based on these data it is conceivable that oncogenic Ras,
which is frequently mutated in AML, renders hematopoietic
cells insensitive to TGF-β treatment through modulation of
p27 function, resulting in a disturbed negative feedback
control.
In this report, we demonstrate that the leukemic cell lines
TF-1 and HL-60, bearing oncogenic N-RasL61 mutations, are
insensitive to TGF-β with regard to cell-cycle arrest. Surpris-
ingly, instead of p27 mislocalization to the cytoplasm, we
found that these leukemic cell lines were devoid of p27. A
Ras/MEK/Erk/SKP2-dependent mechanism is responsible
for degradation of p27 and overexpression of p27 in these
cells restored TGF-β–induced cell-cycle arrest.
Materials and methods
Cell culture, (viral) vectors, and transfections
The human and mouse myeloblastic cell lines HL-60 (product no.
CCL-240; ATCC, Manassas, VA, USA) and M1 (Product No. TIB-
192, ATCC) were cultured in RPMI 1640 (Biowhittaker, Verviers,
Belgium) supplemented with 100 U/mL penicillin, 100 µg/mL
streptomycin (ICN Biomedicals, Costa Mesa, CA, USA) and 10%
fetal bovine serum (FBS; Bodinco, Alkmaar, the Netherlands). The
human erythroleukemia cell line TF-1 (product no. CRL-2003;
ATCC) was cultured in RPMI 1640, supplemented with 10% FBS
and 10 ng/mL granulocyte monocyte-colony stimulating factor
(Genetics Institute, Cambridge, MA, USA).
pBabe FLAG-27 was constructed by ligating the EcoRI-XhoI
fragment of pCDNA3 FLAG-p27 into the pBabe-Ires-GFP puro
plasmid. TF-1 cells were transduced with viral particles collected
from Phoenix cultures transfected with pCL-AMPHO and pBabe
Flag-p27 using FuGENE6 (Roche, Almere, The Netherlands). Cells
stable expressing FLAG-p27 were continuously selected with 1
µg/mL puromycine (Sigma, St. Louis, MO, USA).
TF-1 cells were electroporated (960 µF, 240 V) with 15 µg of
pCMV Tag2B or pCDNA3 FLAG wt p27 or S10A, T157A, S161A,
T162A, S178A, or T187A mutant p27 in order to study degradation.HL-60 and TF-1 cells were either mock electroporated (960 µF,
240 V) or 1) with 12.5 µg pGAL4-Elk1, 12.5 µg pGAL4-TK-luc
and 5 µg pDM2-LacZ for the Elk-Gal4 transactivation assay, 2)
with 12.5 µg 7X Smad binding element (SBE) luciferase and 12.5
µg pDM2-LacZ for the TGF-β reporter assay, or 3) with the p27GL-
1609 reporter plasmid [37] in order to study p27 transcription.
All reporter transfections were collected in 100 µL reporter
lysis buffer (Promega Corp, Leiden, the Netherlands) and subjected
to luciferase and β-galactosidase assays as described previously
[38].
Reagents and antibodies
The p16, p27(C-19), p57(C20), P-p27 Ser10, Erk (K-23), N-
Ras(C20), Rb(C15), and Smad4, antibodies were obtained from
Santa Cruz Biotechnology (Santa Cruz, CA, USA). Smad3, SKP2,
p27, and P-p27 Thr187 were purchased from Zymed Laboratories
(South San Francisco, CA, USA). P-Erk antibody was obtained
from New England Biolabs (Beverly, MA, USA). Flag antibody,
p21 antibody, and an antibody against Actin (C4) were obtained
from Sigma, Transduction Laboratories (Lexington, KY, USA)
and ICN Biomedicals, respectively. All antibodies were reactive for
both human and mouse isoforms. Horseradish peroxidase-labeled
secondary antibodies were obtained from DAKO (Glostrup,
Denmark). The farnesyl transferase inhibitor L744832 and the MAP
kinase/ERK kinase (MEK) 1 inhibitor U0126 were obtained from
Biomol (Plymouth Meeting, PA, USA) and Promega Corp., respec-
tively. TGF-β was purchased from R&D systems (Minneapolis,
MN, USA). MG132 was obtained from Calbiochem (Darmstadt,
Germany). Nocodazole, Actinomycin D, Cycloheximide, Puromy-
cin, RNase A, propidium iodide (PI), and Triton X-100 were ob-
tained from Sigma. Sodium citrate-dihydrate was purchased from
Merck (Darmstadt, Germany).
Ras binding reaction
TF-1, HL-60, and M1 cells (5 × 106) were incubated in 2 mL
RPMI 1640 medium supplemented with 0.5% FBS for 24 hours.
Cells were lysed in 400 µL lysis buffer and a Ras binding reaction
was performed as described previously [36].
Mutation analysis of N-Ras
Mutation analysis of N-Ras was performed by single-strand confor-
mation polymorphism (SSCP). Genomic DNA was extracted from
HL-60 and TF-1 cells and polymerase chain reaction (PCR) analysis
was performed as described previously [36,39].
Preparation of protein extracts and Western blot analysis
The amount of p27, p21, p16, p57, Erk, SKP2, Ras, FLAG, Smad3,
Smad4, and actin, and the degree of phosphorylated p27 and Erk
were determined by Western blotting on whole cell extracts, cyto-
plasmic, or nuclear extracts. Total cell extracts were prepared by
resuspending the cells in lysis buffer (20 mM Tris-HCl, pH 7.6;
100 mM NaCl; 10 mM ethylenediaminetetraacetic acid [EDTA]; 1%
NP-40; 10% glycerol; 2 mM Na3VO4; 2 mM phenylmethylsulfonyl
fluoride [PMSF]; 1 µM pepstatin; and 1 mM dithiothreitol [DTT])
and kept for 15 minutes on ice.
For cytoplasmic and nuclear extracts, cells were lysed according
to the “mini extracts” method [40]. All extracts were normalized
for protein content prior to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). Proper fractionation and lack of
leakage of nuclear proteins to the cytosol was determined with
Western blotting for the nuclear protein retinoblastoma.
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Cells (2 × 107) were cultured for 24 hours in RPMI 1640 medium
supplemented with 10% FBS. Cells were washed with ice-cold
PBS and subsequently lysed in 500 µL lysis buffer (20 mM
Tris-HCl, pH 7.6; 100 mM NaCl; 10 mM EDTA; 1% NP-40;
10% glycerol; 2 mM Na3VO4; 2 mM PMSF; 1 µM pepstatin; and
1 mM DTT) for 10 minutes on ice. Cell lysates were clarified at
5000g for 10 minutes and after preclearing with 30 µL Protein A
Sepharose beads for 1 hour at 4C, cell lysates were incubated
with 5 µL SKP2 or p27 antibody (Zymed) and rotated for 4 hours
at 4C. Protein A sepharose beads (30 µL) were added to each
sample and incubated for 16 hours at 4C. The immune complex
was washed three times with lysis buffer. The immune complexes
were heated in sample buffer, separated by SDS-PAGE, immu-
noblotted on polyvinylidine difluoride membrane (Millipore), and
incubated for 16 hours with either anti-SKP2 or anti-p27 antibody.
Immunocomplexes were detected using enhanced chemilumines-
cence (ECL).
Fluorescein-activated cell sorting
TF-1, HL-60, and M1 cells were synchronized with 0.33 µM Noco-
dazole. After 16 hours cells were washed three times and plated
at 0.25 × 106/1.5 mL and treated with TGF-β (2 ng/mL), 0.001%
dimethylsulfoxide (DMSO), U0126 (10 µM), or L744832 (50 µM)
as indicated. After 72 hours, cells were washed and incubated
with PI solution (0.1 µg/µL RNase A, 0.96 mg/mL sodium citrate
dihydrate, 0.02 µg/µL PI, 0.1% Triton X-100) for 20 minutes at
room temperature. Binding of PI was measured using fluorescein-
activated cell sorting (FACS; Becton Dickinson, Sunnyvale, CA)
and cell-cycle analysis was performed using ModFit LT.
Quantitative PCR
RNA extraction, preparation of cDNA, and quantitative PCR
(Q-PCR) for Smad7, SnoA, SKP2, p15, p18, and p27 were per-
formed as described previously [41]. Primers used: Smad7 For
gcctcggacagctcaattcg; Smad7 Rev cgtccacggctgctgcataa; SnoA
For cattctcacagatcacctgac; SnoA Rev gtcttacttctctcacaggatg; SKP2
For ccagcaagacttctgaac; SKP2 Rev ggaggcacagacaggaaa; p15 For
cgcgaggagaacaagggcat; p15 Rev gcctcccgaaacggttgact; p18 For
gattgccaggagactgctac; p18 rev cgtgtgcttcaccaggaact; p27 For gcaac-
cgacgattcttctac; p27 Rev gtccattccatgaagtcagc; HPRT For
tggcgtcgtgattagtgatg; HPRT Rev gatgtaatccagcaggtcag. Primers
for SKP2 and the CDKi were designed against conserved regions be-
tween the human and mouse genes. Primers for Smad7 and SnoA
are human-specific.
RNA interference
Short interfering RNA duplexes for SKP2 were made using the
Silencer short interfering RNA (siRNA) construction kit from
Ambion according to the manufacturers protocol (Austin, TX). The
SKP2 target sequences used: AAAGAGGAGCCCGACAGTGAG
and AAGTTGCAGAATCTAAGCCTG. GAPDH control siRNA
duplexes are provided within the kit. TF-1 cells were transfected
with a final concentration of 50 nM or 100 nM of RNA interference
(RNAi) duplexes using oligofectamine according to the manu-
facturer’s protocol (Invitrogen, Breda, The Netherlands). Lysates
were made on the indicated time points in lysis buffer and equal
amounts of protein were subjected to Western blot analysis.
Statistical analysis
The Student’s t-test for paired samples was used to determine
statistical significance of the cell-cycle data.Results
p27 expression and TGF-b–induced
cell-cycle arrest in cells containing oncogenic Ras
The human myeloid leukemic cell line HL-60 and the eryth-
roleukemic cell line TF-1, which have been reported to
contain oncogenic N-Ras mutations [36,42], were studied
with respect to TGF-β–mediated cell-cycle arrest. As a nega-
tive control, the myeloid cell-line M1 was used, because this
cell line contains wt Ras. SSCP analysis confirmed that HL-
60 and TF-1 cells are heterozygous for the N-RasL61 mutation
(data not shown). To determine whether Ras is activated
in these cells, we performed Ras pull-down assays and deter-
mined activation of the downstream effector Erk [2] (Fig.
1a). In HL-60 and TF-1 cells activated Ras and phospho-
p42/44 (P-Erk) were observed, both of which were absent
in M1 cells, although antibodies were capable of recognizing
mouse isoforms (Ras input lane and Erk, data not shown).
To test the effect of TGF-β on the cell-cycle, cells were
synchronized by nocodazole treatment for 16 hours and sub-
sequently cultured in the absence or presence of TGF-β.
FACS analysis demonstrated a minor or no increase in the
percentage of cells in G0-G1 phase of the cell-cycle in
response to TGF-β (HL-60: 46.3 ± 0.7 vs 53.1 ± 0.4; TF-
1: 42.9 ± 1.2 vs 42.1 ± 0.4) (Fig. 1b). This in contrast to
the M1 cell line, which demonstrates an increase of cells in
G0-G1 phase from 48.9% ± 0.5 % to 76.4% ± 2.2%
in response to TGF-β.
Next, Western blot analysis was performed in order to
determine whether the absence of cell-cycle arrest in the
oncogenic Ras-containing cells is related to p27 dysfunction
Figure 1. Cells containing N-Ras mutations are unresponsive to trans-
forming growth factor (TGF)-β and are devoid of p27. (A) TF-1, HL-60,
and M1 cell extracts were Western analyzed for activated Ras, P-Erk, and
p27. After synchronization, cells were harvested and lysed in lysis buffer
and a Ras binding reaction was performed as described in Material and
Methods. Ras denotes activated Ras, which is precipitated with Raf-GDS
glutathione-S-transferase-Ras binding domain precoupled to glutathione-
sepharose beads. Total lysates show amounts of P-Erk, Ras, Actin, and
p27before precipitation. (B) M1, HL-60,and TF-1 cells were synchronized in
M-Phase with Nocodazole and subsequently cultured with or without TGF-
β as indicated. After 72 hours, cells were washed and incubated with PI
solution. Binding of PI was measured using fluorescence-activated cell
sorting and cell-cycle analysis was performed using ModFit LT. The percent
of cells in G0-G1 phase is depicted as mean % G0-G1 ± standard deviation.
H. Schepers et al. /Experimental Hematology 33 (2005) 747–757750[13]. In M1 cells, p27 was located in the nuclear compart-
ment (data not shown and box Fig. 7b). In contrast, no p27
expression was observed in the N-Ras containing HL-60
and TF-1 cells (Fig. 1a). To exclude cell-cycle–dependent
regulation of p27, presence of p27 was analyzed for all cell-
cycle phases after synchronization. As expected, M1 cells
show a cell-cycle–dependent regulation of p27, whereas p27
is absent in all cell-cycle phases in the HL-60 and TF-1 cell
line (data not shown). These observations suggest that the
absence of p27 in cells containing N-Ras mutations might
be involved in the unresponsiveness toward TGF-β.
TGF-b signal transduction is
not impaired in cells with oncogenic Ras
First, we determined whether HL-60 and TF-1 cells are able
to respond to TGF-β or whether the decreased cell-cycle arrest
is due to the absence of p27. Although oncogenic Ras has
been described to be involved in degradation of Smad 4
[33], Figure 2a illustrates that Smad 4 protein is present
in the HL-60 and TF-1 cell lines in levels comparable to
M1 cells.
In addition, TGF-β signal transduction can be inhibited
by modulating the cytoplasmic to nuclear translocation of
Smad 2/3 through an Erk 1/2-dependent mechanism [34],
which has been described to be activated by Ras in hemato-
poietic cells [2]. In the N-Ras–containing cells, Smad 3
nuclear accumulation was observed in response to TGF-β
treatment (Fig. 2b), indicating that Ras does not interfere
with cytoplasmic to nuclear shuttling of Smad 3.Finally, TGF-β responsive target genes (including Smad
7 and SnoA) were studied by means of Q-PCR (Fig. 2C).
In both HL-60 and TF-1 cells, TGF-β treatment resulted in
an increased expression of these target genes. This observa-
tion was confirmed by a TGF-β reporter assay, where HL-
60 and TF-1 cells were transfected with a reporter construct
containing seven copies of a Smad responsive element (7X
SBE-luciferase). Upon TGF-β treatment, transactivation of
this reporter was observed in both cell lines (Fig. 2d). In
conclusion, these data show that Smad-mediated TGF-β
signaling is normal in these N-Ras containing cells.
Oncogenic Ras regulates p27
through a MEK/Erk-dependent pathway
To demonstrate a connection between Ras signal transduc-
tion and the absence of p27 expression, TF-1 and HL-60
cells were treated with inhibitors of the Ras (L744832) and
MEK/Erk (U0126) pathways. As depicted in Figure 3a, a
reappearance of p27 expression in TF-1 and HL-60 cells is
observed in the presence of inhibitors U0126 and L744832.
The effectivity of the inhibitors was confirmed by reduced
phosphorylation of Erk 1/2 (Fig. 3a and densitometry Fig.
3b) and reduced downstream Elk signaling, as investigated
by an Elk-Gal4 transactivation assay (Fig. 3b).
In order to demonstrate that the effect of Ras/MEK/Erk
signaling is specific for the p27 protein, additional CDKis
were studied. The CDKi p21Waf1 is absent in unstimulated
hematopoietic cells [41], which was confirmed for the HL-
60 cell line. Upon treatment with U0126, no change inFigure 2. TGF-β signal transduction is normal in N-Ras containing HL-60 and TF-1 cells. (A) Smad 4 expression in M1, HL-60, and TF-1 cells. After
24 hours of culture, cell extracts were subjected to Western blot analysis for Smad 4 and Actin. (B) Smad 3 shows nuclear localization after 30 minutes
of TGF-β treatment. HL-60 and TF-1 cells were treated with or without 2 ng/mL TGF-β. Nuclear fractions were isolated and subjected to Western blot
analysis for Smad 3 and Actin. (C) TGF-β activates transcription of target genes in HL-60 and TF-1 cells. Cells were cultured with 2 ng/mL TGF-β for
1 hour and cDNA was prepared as described. Quantitative polymerase chain reaction for Smad 7 and SnoA was performed and normalized against expression
of the common household gene HPRT. Fold inductions are presented as sample mean ± standard deviation relative to untreated samples. (D) TGF-β
transactivates transcription from a 7X SBE-luciferase construct. HL-60 and TF-1 cells were electroporated with a 7x SBE Luciferase vector and pDM2-
LacZ. After 24 hours, cultures were split in two and treated for 16 hours with or without 2 ng/mL TGF-β. Cell extracts were subjected to luciferase and
β-galactosidase assays as described. Luciferase values were normalized against β-galactosidase activity and fold inductions are presented as sample mean
± standard deviation relative to untreated samples.
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levels in TF-1 and HL-60 cells. (A) Treatment with U0126 and L744832
restores p27 protein levels in TF-1 and HL-60 cells. Cells were cultured
for 16 hours in the presence of 10 µM U0126 or 50 µM L744832. Cell
extracts were subjected to Western blot analysis for P-Erk, total Erk, and
p27. (B) Densitometry of P-Erk and Elk reporter activity indicate inhibition
of Ras/MapK signaling by U0126 and L744832. White bars indicate
P-Erk densitometry belonging to Fig. 3a. Black bars indicate normalized
Elk reporter luciferase activity against β-galactosidase activity. HL-60
and TF-1 cells were either mock electroporated or with pGAL4-Elk1,
pGAL4-TK-luc and pDM2-LacZ for the Elk-Gal4 transactivation assay.
Fold inductions are presented as sample means ± standard deviation relative
to untreated samples.
expression of p21 protein was observed (Fig. 4). TF-1 cells
express p21Waf1 (Fig. 4, first lane), which disappears in
the presence of U0126, while no change was observed in the
expression of the CDKi p57Kip2, as is the same for HL-60
cells (Fig.4). The expression of the CDKi p16INK4a is absent in
HL-60 cells,without changes upon U0126 treatment, whereas
in TF-1 cells p16 protein is expressed, which appears to
decrease slightly upon U0126 treatment (Fig. 4). Q-PCR
analysis for the expression of the CDKis p15INK4b and
p18INK4c demonstrated no significant changes upon U0126
treatment (data not shown).
Although some changes are observed for p21 and, to a
lesser extent, p16 upon U0126 treatment, the most prominent
effect was observed on p21 expression levels, which were
strongly reduced by U0126 treatment and this would posi-
tively affect cell-cycle progression. These data strongly sug-
gest that the blockade of TGF-β–induced cell-cycle arrest by
Ras/MEK/Erk signaling in TF-1 and HL-60 cells is mediated
through modulation of the p27 expression levels, because
none of the other CDKis are upregulated after U0126
treatment.Figure 4. Inhibition of MapK signal transduction does not upregulate other
cyclin-dependent kinase inhibitors. The CDKi p21 disappears upon U0126
treatment and the expression of the CDKi’s p16 and p57 is not changed
upon treatment with U0126. TF-1 and HL-60 cells were cultured for 16
hours in the presence or absence of 10 µM U0126. Cell extracts were
subjected to Western blot analysis for p21, p57, p16, and Actin.
TGF-b–mediated cell-cycle arrest is restored after
U0126 and L744832 treatment and is p27-dependent
To demonstrate that reappearance of p27 is associated with
TGF-β–mediated cell-cycle arrest, TF-1 cells were stimu-
lated with TGF-β in the presence of U0126 or L744832. A
significant increase in the percentage of cells in G0-G1 phase
(Fig. 5a, 13.6% and 7.2% respectively, * and **  p 0.05)
was demonstrated by FACS analysis.
To study the specificity of this effect, a TF-1 cell culture
was generated in which the cells stably express p27 through
retroviral transduction with pBabe-Flag-p27. In these cells,
cell-cycle analyses were performed with TGF-β in the ab-
sence and presence of the MEK/Erk inhibitor U0126. Mock
(pBabe) transfected TF-1 cells have a minor increase in the
percentage of cells in G0-G1 phase after TGF-β treatment
(Fig. 5b, 7.2%, p  0.05) and this increase can be enhanced
by inhibiting the MEK/Erk pathway (20.8 %, •  p 0.05).
TF-1 cells expressing pBabe-Flag-p27 already show an
almost twofold increase in the percentage of cells in G0-G1
phase (21.6%, ••  p  0.01) in response to TGF-β, which
was not further enhanced by U0126 treatment (18.3 %,
•••  p 0.01) (Fig. 5b). These results clearly indicate that
the presence of p27 is sufficient to increase the percentage
of cells in G0-G1 phase upon TGF-β treatment, although
the percentages of untreated cells in G0-G1 phase varied
between the different studied groups. Together, these data
demonstrate that oncogenic Ras inhibits TGF-β–mediated
growth arrest through modulation of p27 levels.
p27 is not regulated at the
transcriptional level, but at the degradation level
p27 protein levels can be regulated at different levels, e.g.,
transcription, translation, or degradation [43]. To study how
p27 protein levels are modulated, cells were pretreated with
the RNA polymerase II inhibitor Actinomycin D. Al-
though Actinomycin D was effective because it completely
blocked TGF-β–induced transcription of Smad 7 (Fig. 6b),
H. Schepers et al. /Experimental Hematology 33 (2005) 747–757752Figure 5. TGF-β–mediated cell-cycle arrest is p27-dependent and can be restored by inhibition of MapK and Ras signal transduction. (A) TGF-β–mediated
cell-cycle arrest can be restored upon inhibition of the MapK and Ras signal transduction pathways. TF-1 cells were synchronized in M-Phase and subsequently
cultured with or without TGF-β in the presence of dimethylsulfoxide, U0126, or L744832 as described. After 72 hours, cells were washed and incubated
with PI solution. Binding of PI was measured using fluorescence-activated cell sorting and cell-cycle analysis was performed using ModFit LT. The percent
of cells in G0-G1 phase is depicted as mean % G0-G1 ± standard deviation. * and **  p  0.05. (B) Stable overexpression of FLAG-p27 is sufficient to
restore TGF-β–mediated cell-cycle arrest. TF-1 cells were either mock (pBabe) stable transfected or with pBabe-FLAG-p27 and selected for positive cells
with puromycin. The cells were synchronized in M-Phase and subsequently cultured with or without TGF-β or U0126. After 72 hours, cell-cycle
analysis was performed as described above. The percent of cells in G0-G1 phase is depicted as mean % G0-G1 ± standard deviation. * and •  p  0.05,
•• and •••  p  0.01. Cell extracts were also subjected to Western blot analysis for FLAG and Actin.p27 still reappeared after U0126 and L744832 treatment
(Fig. 6a, middle panel, compare with left panel, the control
for p27 reappearance). No significant upregulation of p27
transcription after U0126 treatment was observed with
Q-PCR studies for p27 mRNA, which was confirmed by
reporter assays with the p27GL-1609 construct [37] in the
TF-1 and HL-60 cells (data not shown).
Treatment with the proteasome inhibitor MG132 induced
reappearance of the p27 protein (Fig. 6a, right panel), sug-
gesting that oncogenic Ras regulates p27 protein levels
through degradation. In view of these data, the mRNA and
protein expression levels of SKP2, the E3 ubiquitin ligase
of p27, were analyzed. As depicted in Figure 6c and d, in
the HL-60 and TF-1 cell lines SKP2 expression levels are
fourfold increased as compared to M1 cells.
Subsequently, we determined whether Ras signaling en-
hanced SKP2 levels via an Erk-dependent pathway resulting
in p27 degradation. Treatment of HL-60 cells with the Ras
inhibitor L744832 resulted in reduced levels of phosphory-
lated Erk, downregulation of SKP2 expression and the reap-
pearance of p27 protein (Fig. 6e). In addition, M1 cells
transiently transfected with pCDNA3-Myc-N-RasL61 dem-
onstrated higher SKP2 protein levels than mock transfected
control cells (data not shown). These data suggest that onco-
genic Ras promotes p27 degradation through the activation
of Erk and subsequent upregulation of SKP2 expression.
p27 Regulation involves degradation
Degradation of p27 has been described to involve two major
steps, phosphorylation and ubiquitinylation [18]. Phosphory-
lation of p27 at Threonine 187 has been shown to occur
through Cyclin E/CDK2 complexes in the nucleus, followed
by binding of the F-box protein and E3 ubiquitin ligaseSKP2 [19–23]. Phosphorylation of p27 at Serine 10 also has
been shown to occur by a yet unknown kinase, followed by
nuclear export and degradation in the cytoplasm [30,31,
44–46]. In order to investigate the mechanism involved in
p27 degradation in N-Ras–containing cells, alanine point
mutants from known and putative phosphorylation sites, were
transiently transfected into TF-1 cells. After 24 hours, cultures
were split and treated with U0126 (Fig. 7a). Although to
slightly different levels, treatment with U0126 resulted in
reappearance of wild-type (Wt) and all p27 point mutants
proteins. Strikingly, the p27T187A mutant was resistant to
degradation in TF-1 cells (Fig. 7a, upper and lower panel),
indicating that this phosphorylation site is relevant for p27
degradation in the presence of oncogenic Ras.
Subsequently, degradation of p27 was studied in more
detail. Virally transduced Flag-p27 TF-1 cells were treated
with both the proteasome inhibitor MG132 and the transla-
tion inhibitor cycloheximide. This provides the opportunity to
investigate steady-state levels of p27 in the cell. In addition,
it is possible to study whether p27 is phosphorylated and
whether degradation of p27 is a nuclear event.
After 18 hours of culture, p27, phosphorylated at serine 10
and threonine 187, was confined to the nuclear compartment
without modulation by U0126 treatment (Fig. 7b). In addi-
tion, Flag-p27 was only detected in the nuclear compartment
(Fig. 7b), suggesting that degradation of p27 occurs solely
in the nucleus and no nuclear to cytoplasmic translocation
takes place. The box next to panel B demonstrates the ab-
sence of p27 in both nuclear and cytoplasmic fractions in
untreated parental TF-1 cells. M1 cells are shown as control.
Moreover, these findings implicate that the phosphorylation
of T187 is a prerequisite for p27 degradation, but it is
H. Schepers et al. /Experimental Hematology 33 (2005) 747–757 753Figure 6. p27 is not regulated at the transcriptional level but at the degrada-
tional level in N-Ras containing cells and SKP2 is regulated by a Ras-
dependent pathway. (A) Actinomycin D does not affect p27 restoration
after U0126 and L744832 treatment and p27 levels are restored after treat-
ment with the proteasome inhibitor MG132. TF-1 cells were cultured for
16 hours in the presence or absence of U0126, L744832, or 0.25 µM
MG132 with or without 0.50 µg/mL Actinomycin D. Cell extracts were
subjected to Western blot analysis for p27 and Actin. (B) Actinomycin D
is effective in blocking TGF-β–induced transcription of Smad 7. TF-1 cells
were cultured with 2 ng/mL TGF-β for 1 hour, with or without pretreatment
with 0.50 µg/mL Actinomycin D. cDNA was prepared as described and
Q-PCR for Smad 7 was performed and normalized against expression
of the common house hold gene HPRT. Fold inductions are presented
as sample means ± standard deviation relative to untreated samples. (C)
Q-PCR for SKP2 indicates higher mRNA levels in N-Ras containing
HL-60 and TF-1 cells. Cells were cultured and cDNA was prepared as
described. Q-PCR for SKP2 was performed and normalized against ex-
pression of the common household gene HPRT. Fold inductions are pre-
sented as sample mean ± standard deviation relative to M1 control cells.
(D) Western blot analysis for SKP2 indicates higher protein levels in
N-Ras containing HL-60 and TF-1 cells. Cells were cultured and cell
extracts were subjected to Western blot analysis for SKP2 and Actin. (E)
Inhibition of Ras signal transduction decreases P-Erk and SKP2 levels and
increases p27 levels. HL-60 cells were cultured with or without L744832.
After 16 hours, cells were lysed and cell extracts were subjected to Western
blot analysis for P-Erk, total Erk, SKP2, and p27.
unlikely to be the cause of degradation. It is more conceiv-
able that the elevated SKP2 levels are connected with the
increased degradation of p27. Subsequently, coimmunoprec-
ipitation studies were performed in the virally transduced
Flag-p27 TF-1 cell line, to demonstrate complex formation
between p27 and SKP2. Indeed, p27 can be precipitated with
SKP2 (Fig. 7c, Left panel) and, vice versa, SKP2 precipitates
with p27 (Right panel), indicating that these two proteins are
in the same complex in the TF-1 cell line.
Finally, to study whether SKP2 is involved in p27 degra-
dation in N-Ras–containing cells, RNAi studies for SKP2
were performed in the TF-1 cell line. Knockdown of
SKP2 resulted in a reappearance of p27 protein, without an
effect on GAPDH or actin levels (Fig. 7d). Conversely,
siRNA oligos for GAPDH only affect GAPDH expressionlevels and had no effect on p27. These data further support
a role for SKP2 in p27 degradation.
Discussion
Loss of responsiveness to antiproliferative signals of growth
factors, such as TGF-β, might provide a growth advantage
to malignant cells [47]. Here we show that leukemic cells
that carry an oncogenic N-RasL61 mutation escape TGF-β–
mediated cell-cycle arrest through nuclear degradation of
the CDKI p27Kip1/Waf1 in a Ras/MEK/Erk/SKP2-dependent
manner. This finding highlights an alternative pathway
that results in TGF-β unresponsiveness. Among these alter-
native pathways are phosphorylation of Smad 3 and subse-
quent inhibition of nuclear translocation of this protein [34],
the degradation of Smad 4 [33], and mislocalization of p27
to the cytoplasm [13].
In this study, we demonstrate that cells with N-Ras muta-
tions have elevated SKP2 protein levels, a link that has
been observed before [48]. In other cellular settings, SKP2-
independent regulation of p27 has been reported, which
coincided with Erk activation and involved translocation
of p27 to the cytoplasm [49]. Phosphorylation on different
residues has been demonstrated to be involved in cyto-
plasmic localization and or stabilization of p27, e.g., Serine
10, Threonine 157, and Serine 178 [27,29,30,50]. In our
experiments, we observed that alanine point mutants of S10
and S178 are upregulated to higher levels then other mutants
by U0126 treatment (Fig. 7a), suggesting additional cyto-
plasmic degradation routes of p27. However, we show that
p27 is not translocated to the cytoplasm, even though p27
is phosphorylated on residue S10 (Fig. 7b). The observed
differences in expression between the various alanine point
mutants are therefore likely to be the results of different
transfection efficiencies. The only phosphorylation mutant
that was resistant to degradation was the p27T187A mutant,
suggesting SKP2-dependent nuclear degradation [18–23,
30,31,46]. However, inhibition of the MEK/Erk pathway
did not modulate phosphorylation of the T187 residue, sug-
gesting that p27 phosphorylation is a prerequisite for bind-
ing to SKP2, but not the primary cause for the degradation
process. Upregulation of SKP2 expression and binding to p27
in the nucleus seems to be the primary cause of the increased
degradation of p27. The observed difference between our
results and additional studies [49] is therefore likely to be
cell-type–dependent.
Recently, TGF-β was demonstrated to destabilize SKP2
by ubiquitin-mediated proteolysis and decreased levels of
Cks1 mRNA [51]. This, in turn, stabilized the p27 protein
and resulted in cell-cycle arrest. In our study, however, TGF-
β treatment of Wt TF-1 cells did not lead to an increase in
p27 levels, probably because oncogenic Ras upregulates
SKP2 to such levels that reduction of SKP2 by TGF-β is not
sufficient to prevent p27 degradation by SKP2. Although
it is reported that deletion of p27 causes hyperproliferation
H. Schepers et al. /Experimental Hematology 33 (2005) 747–757754Figure 7. p27 protein is degraded in a Phospho Threonine 187/SKP2-dependent manner. (A) Mutant p27T187A is resistant to degradation. TF-1 cells were
electroporated with pCMV Tag2B or pCDNA3 FLAG wt p27 or S10A, T157A, S161A, T162A, S178A, or T187A mutant p27. After 24 hours, cultures
were split in two and for 16 hours treated with or without U0126. Cell extracts were subjected to Western blot analysis for FLAG and Actin. (B) p27
is phosphorylated on S10 and T187 and is specific nuclear localized. Stable expressing pBabe-FLAG-p27 TF-1 cells were cultured for 16 hours in the
presence of 0.25 µM MG132 and 100 µg/mL cycloheximide (CHX) with or without 10 µM U0126. Cytoplasmic and nuclear fractions were isolated and
subjected to Western blot analysis for Flag p27, phospho Ser10 p27, phospho Thr187 p27, Rb, and Actin. The box demonstrates the absence of p27 from
both nuclear and cytoplasmic fractions in TF-1 cells. M1 cells are shown as a control. (C) SKP2 and p27 form a complex in N-Ras–containing TF-1 cells.
Stable expressing pBabe-FLAG-p27 TF-1 cells were cultured for 16 hours and cell extracts were subjected to coimmunoprecipitation (IP) studies between SKP2
and p27 as described in Material and Methods. The precipitates were subjected to Western blot analysis for SKP2 or p27. IP indicates samples subjected
to IP procedure, total indicates samples before IP procedure and beads indicates IP procedure without antibody to exclude aspecific binding (D) p27 protein
is reappearing after RNA interference for SKP2. TF-1 cells were transfected with siRNA oligos for SKP2 and GAPDH as described and at the indicated
time points cell were lysed and extracts were subjected to Western blot analysis for SKP2, p27, GAPDH, and Actin.[52], overexpression of FLAG-p27 itself is not enough to
induce growth arrest in TF-1 cells. This suggests the activa-
tion of an additional signal transduction pathway by TGF-
β. Alternatively, there is a persistent disbalance in the SKP2
and p27 levels, resulting in an inappropriate activation of
cell-cycle progression. In the stable FLAG-p27 cells, an
increased expression of p21 was observed and in some
experiments p15 (data not shown). Because p27 has been
demonstrated to enhance Sp1 stability and promoter binding
[53] and both p21 andp15 expression is enhanced by Sp1 [54],
upregulation of p21 and p15 could be an effect of p27-
mediated Sp1 activation. These two CDKis might contribute
to p27-mediated growth arrest in response to TGF-β, but
they are downstream of p27.
P27 protein degradation is complex and controlled by
various mechanisms. In this report, we show that p27 protein
levels are regulated by degradation through a T187 phos-
phorylation-dependent, MEK/Erk-dependent, SKP2 path-
way. Different signaling pathways downstream of MEK/Erk
have been identified that affect SKP2 expression. Cul1, a
critical component of the SCF(SKP2) ubiquitin ligase isa direct transcriptional target of c-Myc [55]. It has been
demonstrated that Myc expression and activity is downregu-
lated upon MEK1 inhibition in conjunction with upregula-
tion of p27 [56]. Indeed, inhibition of Ras activity with
L744832 resulted in decreased c-Myc protein levels (data
not shown), in accordance with reduced SKP2 levels and
restoration of p27 levels (Fig. 6e). Alternatively, the SKP2
gene has been demonstrated to be a transcriptional target of
GA binding protein (GABP) [57] and DNA microarray stud-
ies have indicated that GABP is a target gene of MEK/ERK
signaling [58]. Both possibilities support our findings that
1) MEK/Erk signaling does not directly influence the phos-
phorylation status of p27 nor the transcription of p27 and
2) that delayed upregulation of p27 upon inhibition with
U0126 and L744832 indicates an indirect effect of MEK/
Erk signaling.
The inhibitory effect of p27 on the cell cycle is not re-
stricted to the effects of TGF-β. Similar findings have been
observed in solid tumors in response to vitamin D and reti-
noic acid [59,60]. Because N-Ras transformed teratocar-
cinoma and prostate epithelial cells are resistant to retinoic
H. Schepers et al. /Experimental Hematology 33 (2005) 747–757 755acid [61,62] the previously described mechanism of dis-
turbed p27 degradation widens the extent of enhancing the
proliferative capacity of cells bearing oncogenic Ras muta-
tions. Recently, studies demonstrated that unfavorable treat-
ment results in AML were associated with elevated SKP2
levels and with a high cytoplasmic to nuclear p27 ratio
[35,63]. Although in our model, cytoplasmic p27 was not
observed, the high cytoplasmic to nuclear ratio in these
studies might be due to nuclear degradation of p27 in a
SKP2-dependent manner, thereby increasing the cytoplasmic
p27 relative to the nuclear p27 levels. Ras-GTP and down-
stream targets can modulate these pathways in several ways,
because Ras activation can be triggered directly by muta-
tions in the Ras oncogene, or indirectly by mutations in the
PTPN11 gene, encoding for the protein tyrosine phospha-
tase SHP-2 [64] (and references therein), indicating the
complexity of the mechanisms leading to oncogenic transfor-
mation and proliferation.
Recently, different phase I-II studies have been initiated
to interfere with Ras-mediated signaling in AML patients
and to increase the susceptibility of the leukemic cells for
the cytotoxic effects of chemotherapy [65–67]. This report
indicates that this is not the only advantage of this approach.
AML cells might also become more susceptible for negative
regulatory molecules that limit cell proliferation, including
TGF-β.
In conclusion, we demonstrate that hematopoietic cells
with N-Ras mutations do not respond to the inhibitory
effects of TGF-β on cell-cycle progression, as a result of
the absence of p27.This is due to a constitutive nuclear
degradation of p27 in a Ras/MEK/Erk/SKP2-dependent
manner.
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